To summarize, the IL-6/JAK/STAT3 signaling pathway mediates breast cancer progression, metastasis, and therapeutic resistance thus justifying investigations into IL-6/JAK/STAT3 as a targeted therapy for breast cancer patients. This evidence concerns the gene IL6 and breast carcinoma.